BamSEC and AlphaSense Join Forces
Learn More

Celcuity Inc. – Material Contracts

NASDAQ: CELC    
Share price (10/1/26): $75.13    
Market cap (10/1/26): $3.676 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.11
from 10-Q 5 pages Celcuity Inc. 2026 Stock Incentive Plan Stock Appreciation Rights Agreement
12/34/56
EX-10.10
from 10-Q 5 pages Celcuity Inc. 2026 Stock Incentive Plan Performance Stock Unit Agreement
12/34/56
EX-10.9
from 10-Q 6 pages Celcuity Inc. 2026 Stock Incentive Plan Performance Stock Unit Agreement
12/34/56
EX-10.8
from 10-Q 4 pages Celcuity Inc. 2026 Stock Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.7
from 10-Q 5 pages Celcuity Inc. 2026 Stock Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.6
from 10-Q 6 pages Celcuity Inc. 2026 Stock Incentive Plan Restricted Stock Agreement
12/34/56
EX-10.5
from 10-Q 7 pages Celcuity Inc. 2026 Stock Incentive Plan Stock Option Agreement
12/34/56
EX-10.4
from 10-Q 7 pages Celcuity Inc. 2026 Stock Incentive Plan Stock Option Agreement
12/34/56
EX-10.3
from 10-Q 6 pages Celcuity Inc. 2026 Stock Incentive Plan Stock Option Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Celcuity Inc. Amended and Restated 2017 Employee Stock Purchase Plan
12/34/56
EX-10.2
from 8-K 11 pages Celcuity Inc. Amended and Restated 2017 Employee Stock Purchase Plan
12/34/56
EX-10.1
from 8-K 19 pages Celcuity Inc. 2026 Stock Incentive Plan
12/34/56
EX-10.40
from 10-K 4 pages Celcuity Inc. 2017 Stock Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.1
from 8-K 3 pages Celcuity Reports Clinical Data From Two Early Phase Studies of Gedatolisib - In the Phase 1 Portion of the CELC-G-201 Clinical Trial Evaluating Gedatolisib Plus Darolutamide in Men With Metastatic Castration Resistant Prostate Cancer (“McRpc”), the Six-Month Radiographic Progression Free Survival (“Rpfs”) Rate Was 66% - In a Phase 2 Clinical Trial of Gedatolisib Plus Trastuzumab-Pkrb as 3l+ Therapy in Patients With Her2+ Metastatic Breast Cancer (“Mbc”), the Objective Response Rate (“Orr”) Was 43% - No Patients Discontinued Gedatolisib Due to a Treatment-Related Adverse Event (“Ae”) in Either Clinical Trial
12/34/56
EX-10.1
from 8-K 11 pages Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan
12/34/56
EX-10.2
from 10-Q 5 pages Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan Stock Option Agreement
12/34/56
EX-10.35
from 10-K 10 pages Celcuity Inc. Change in Control and Severance Plan and Summary Plan Description
12/34/56
EX-10.2
from 10-Q 3 pages Celcuity Inc. Non-Qualified Stock Option Transfer Agreement
12/34/56
EX-10.1
from 10-Q 1 page Amended Agreement Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan Amendment to Stock Option Agreement
12/34/56
EX-10.1
from 8-K 1 page Amendment to the Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan May 9, 2024
12/34/56